<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365728">
  <stage>Registered</stage>
  <submitdate>31/01/2014</submitdate>
  <approvaldate>5/02/2014</approvaldate>
  <actrnumber>ACTRN12614000142639</actrnumber>
  <trial_identification>
    <studytitle>Effects of intravenous caffeine on Fractional Flow Reserve measurements in coronary artery disease</studytitle>
    <scientifictitle>To compare fractional flow reserve (FFR) before and after intravenous caffeine administration in coronary artery disease patients to evaluate effect of caffeine on FFR levels</scientifictitle>
    <utrn>U1111-1152-8715</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Coronary artery disease
</healthcondition>
    <healthcondition>Ischaemic heart disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Fractional flow reserve measurements performed as clinically required.
intravenous caffeine administration 4mg/kg (maximum 400 mg IV) 
Repeat fractional flow reserve measurements 10 minutes after caffeine administration</interventions>
    <comparator>Patients prior FFR measurements serve as control measurement,  second FFR measurement done post caffeine administration </comparator>
    <control>Uncontrolled</control>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Any statistical significant change FFR measurements after caffeine administration.</outcome>
      <timepoint>After completion of second FFR measurement.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Any clinically significant change in FFR measurements. (defined as crossing cutoff values of 0.80; i.e.: decrease in FFR above 0.80 to below 0.80) </outcome>
      <timepoint>After completion of second FFR measurement.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Moderate coronary artery disease requiring FFR measurements. 
FFR measurement &lt;0.90 
Valid consent
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Inability to give informed consent
Caffeine contraindicated
Adenosine contraindicated</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>As patients serve as their own control; no allocation concealment procedures will need to be applied. </concealment>
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>Students T test will be used to compare two groups (pre and post caffeine administration.)
This is a proof of concept trial ; and will help determine number needed for a larger randomised trial</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/11/2011</anticipatedstartdate>
    <actualstartdate>5/12/2011</actualstartdate>
    <anticipatedenddate>1/03/2012</anticipatedenddate>
    <actualenddate>15/06/2012</actualenddate>
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>The Northern Hospital - Epping</hospital>
    <postcode>3076 - Epping</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>The Northern Hospital</primarysponsorname>
    <primarysponsoraddress>185 Cooper Street
Epping Vic 3076</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>The Northern Hospital</fundingname>
      <fundingaddress>185 Cooper Street
Epping Vic 3076</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Intravenous adenosine is used to minimize the coronary micro-resistance to achieve maximal hyperemia along with nitrates for optimal fractional flow reserve (FFR) measurements. We hypothesize that caffeine, being a competitive inhibitor of adenosine, would influence adenosine mediated FFR readings. 

Consecutive patients undergoing angiogram and FFR measurements were enrolled after abstaining from caffeine for 24 hours. Patients with any contraindications to intravenous adenosine or caffeine were excluded. FFR measurements were taken using nitrates and adenosine pre and post 4mg/kg intravenous caffeine administration and results were compared.
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Northern Health HREC</ethicname>
      <ethicaddress>185 Cooper Street
Epping vic 3076</ethicaddress>
      <ethicapprovaldate>18/11/2011</ethicapprovaldate>
      <hrec>P18/11</hrec>
      <ethicsubmitdate>1/11/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>William J van Gaal</name>
      <address>The Northern Hospital
185 Cooper street
Epping 
Vic 3076</address>
      <phone>+61384058389</phone>
      <fax />
      <email>william.vangaal@nh.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Vivek Mutha</name>
      <address>The Northern Hospital
185 Cooper street
Epping 
Vic 3076</address>
      <phone>+61384058000</phone>
      <fax />
      <email>vivek.mutha@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Vivek Mutha</name>
      <address>The Northern Hospital
185 Cooper street
Epping 
Vic 3076</address>
      <phone>+61384058000</phone>
      <fax />
      <email>vivek.mutha@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>